Mumbai-based Sun
Pharmaceutical Industries has
announced a US$48 million
agreement under which a Sun
Pharma subsidiary has offered to
acquire InSite Vision.
InSite Vision focuses on
developing new specialty
ophthalmic products, including
three late stage programs, while
Sun Pharma is in the process of
establishing a branded ophthalmic
business in the US.
This proposed acquisition of InSite
Vision, coupled with the recent
in-licensing of Xelpros (latanoprost
BAK-free eye drops) in June this
year, are steps in this direction, the
company said.
These deals also give Sun Pharma
access to four late stage branded
ophthalmic products in the US.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Sep 15
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.